Detalles de la búsqueda
1.
Influence of dispersion slope on the diagnosis of liver fibrosis by the shear wave in metabolic dysfunction-associated steatotic liver disease.
Hepatol Res;
2024 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38806293
2.
Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.
Cancer Med;
13(5): e7025, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38477514
3.
Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab.
Oncology;
102(3): 239-251, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37729889
4.
Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial.
Yonago Acta Med;
66(4): 422-431, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38028262
5.
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Cancers (Basel);
15(22)2023 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38001666
6.
Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma.
Commun Med (Lond);
3(1): 152, 2023 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37880538
7.
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Liver Cancer;
12(3): 251-261, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37601981
8.
The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib.
Oncology;
101(8): 491-501, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37429266
9.
Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
BMC Gastroenterol;
23(1): 222, 2023 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37380950
10.
Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein.
Cancers (Basel);
15(8)2023 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37190231
11.
Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions.
Cancers (Basel);
15(3)2023 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36765804
12.
Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma.
Intern Med;
62(12): 1771-1774, 2023 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36328580
13.
Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices.
BMC Gastroenterol;
22(1): 535, 2022 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36550416
14.
Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma.
Cancers (Basel);
14(20)2022 Oct 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36291850
15.
Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
J Gastroenterol;
57(9): 676-683, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35849192
16.
Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study.
BMC Gastroenterol;
22(1): 275, 2022 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35655156
17.
Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Liver Cancer;
11(2): 174-177, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35634428
18.
Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene.
Case Rep Gastroenterol;
16(1): 110-115, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35431768
19.
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.
Cancers (Basel);
14(2)2022 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35053484
20.
The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
PLoS One;
17(1): e0262675, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35041693